MARKET

ASRT

ASRT

Assertio Therapeutics
NASDAQ

Real-time Quotes | Nasdaq Last Sale

0.4901
-0.0219
-4.28%
Pre Market: 0.4901 0 0.00% 04:08 05/12 EDT
OPEN
0.4823
PREV CLOSE
0.5120
HIGH
0.5065
LOW
0.4775
VOLUME
25
TURNOVER
--
52 WEEK HIGH
1.450
52 WEEK LOW
0.3300
MARKET CAP
85.17M
P/E (TTM)
-8.0344
1D
5D
1M
3M
1Y
5Y
70 Biggest Movers From Friday
Gainers InnSuites Hospitality Trust (NYSE: IHT) shares gained 43.4% to close at $3.50 on Friday.
Benzinga · 1d ago
Bausch, Assertio, Lupin must face antitrust claims over diabetes drug Glumetza
Bausch Health Cos Inc, Assertio Therapeutics Inc and Lupin Pharmaceuticals Inc must face claims by purchasers of Bausch's type 2 diabetes drug Glumetza that they conspired to suppress generic competition through an illegal patent settlement, enabling an 80...
Reuters · 4d ago
Assertio shares rise on Q1 revenue strength, provides FY forecast
Assertio Holdings  shares rise ([[ASRT]] +12.1%) after the company posted a 28% jump in first-quarter revenue, and provided financial forecast for the year.Total revenue in the quarter rose to $26.4M
Seekingalpha · 4d ago
Thinking about buying stock in Sundial Growers, Assertio, Regional Health Properties, Palantir Technologies, or Energy Transfer?
, /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for SNDL, ASRT, RHE, PLTR, and ET.
PR Newswire - PRF · 4d ago
Assertio Advances on Q1 Numbers
May 07, 2021 (Baystreet.ca via COMTEX) -- Assertio Holdings, Inc. (NASDAQ: ASRT) saw its shares vault Friday morning, a day after the release of financial...
Baystreet.ca · 4d ago
12 Health Care Stocks Moving In Friday's Pre-Market Session
 
Benzinga · 4d ago
32 Stocks Moving in Friday's Pre-Market Session
Gainers Assertio Holdings, Inc. (NASDAQ: ASRT) shares rose 44.2% to $0.7190 in pre-market trading after the company reported better-than-expected Q1 results.
Benzinga · 4d ago
DJ Assertio Holdings' CEO Dan Peisert on Q1 2021 Results -- Earnings Call Transcript >ASRT
Dow Jones · 5d ago
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of ASRT. Analyze the recent business situations of Assertio Therapeutics through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 2 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average ASRT stock price target is 1.550 with a high estimate of 1.550 and a low estimate of 1.550.
EPS
Institutional Holdings
Institutions: 197
Institutional Holdings: 40.64M
% Owned: 23.43%
Shares Outstanding: 173.79M
TypeInstitutionsShares
Increased
13
3.20M
New
6
76.01K
Decreased
24
5.57M
Sold Out
12
6.20M
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Pharmaceuticals
-0.55%
Pharmaceuticals & Medical Research
-0.29%
Key Executives
Chairman/Independent Director
James Fogarty
President/Chief Executive Officer/Director
Arthur Higgins
Chief Financial Officer/Senior Vice President
Daniel Peisert
Senior Vice President/Chief Technology Officer/Chief Scientific Officer
Stanley Bukofzer
Senior Vice President/Director of Human Resources
Sharon Larkin
Independent Director
Karen Dawes
Senior Vice President
Stan Bukofzer
Independent Director
James Galeota
Senior Vice President
Gerd Kochendoerfer
Independent Director
Heather Mason
Independent Director
William McKee
Independent Director
Peter Staple
Independent Director
James Tyree
Independent Director
Gavin Molinelli
Independent Director
David Wheadon
Independent Director
Robert Savage
No Data
  • All
  • Financials
  • Insiders
More
About ASRT
Assertio Holdings, Inc. is a specialty pharmaceutical company. The Company owns a portfolio of prescription neurology, inflammation and pain medications. Its marketed products include Cambia (diclofenac potassium) for Oral solution, INDOCIN Oral Suspension, INDOCIN (indomethacin) Suppositories, OXAYDO tablets, SPRIX Nasal Spray, VIVLODEX capsules, ZIPSOR Liquid filled capsules and ZORVOLEX capsules. The Company is also focused on developing and commercializing neurology, orphan and specialty medicines. Its pipeline products include Diclofenac Potassium, Long-acting Cosyntropin and Diclofenac potassium. Diclofenac Potassium is being developed for mild/moderate acute pain. Long-acting Cosyntropin is being developed for diagnosis of adrenal insufficiency. Diclofenac potassium is a liquid formulation being developed for acute migraine attacks.

Webull offers kinds of Assertio Holdings Inc stock information, including NASDAQ:ASRT real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ASRT stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading ASRT stock methods without spending real money on the virtual paper trading platform.